Article Type
Changed
Thu, 12/15/2022 - 18:25
Display Headline
2011 San Antonio Breast Cancer Symposium: New therapies, genetic assays translate into early detection of recurrence, encouraging outcomes
The following reports are based on presentations at the San Antonio Breast Cancer Symposium, held December 6–10, 2011.

Bevacizumab improves survival in HER2-positive metastatic disease

Bevacizumab (Avastin) improved progression-free survival (PFS) when added to standard treatment in a study of more than 400 women with human epidermal growth factor receptor 2 (HER2)–positive locally recurrent or metastatic breast cancer.

That finding, which emerged from the AVEREL trial, adds another wrinkle in the ongoing controversy regarding use of bevacizumab in breast cancer treatment.


For the primary endpoint of investigator- assessed PFS, conducted at a median follow-up of 26 months, the addition of bevacizumab resulted in a hazard ratio (HR) of 0.82 (P = 0.0775), compared with treatment with trastuzumab (Herceptin) and docetaxel alone. This difference was not statistically significant. Median investigator-assessed PFS was 16.5 months with bevacizumab versus 13.7 months without it.

In an assessment by an independent review committee (IRC), however, a significant improvement in PFS was seen with the addition of bevacizumab (hazard ratio, 0.72; P = 0.0162). Median IRC-assessed PFS was 16.8 months with bevacizumab, compared with 13.9 months without the drug.

* For a PDF of the full article, click in the link to the left of this introduction.

Article PDF
Author and Disclosure Information

Publications
Topics
Legacy Keywords
San Antonio Breast Cancer Symposium, bevacizumab, HER2-positive, brachtherapy, genetic test, zoledronic acid, DCIS,
Author and Disclosure Information

Author and Disclosure Information

Article PDF
Article PDF
The following reports are based on presentations at the San Antonio Breast Cancer Symposium, held December 6–10, 2011.
The following reports are based on presentations at the San Antonio Breast Cancer Symposium, held December 6–10, 2011.

Bevacizumab improves survival in HER2-positive metastatic disease

Bevacizumab (Avastin) improved progression-free survival (PFS) when added to standard treatment in a study of more than 400 women with human epidermal growth factor receptor 2 (HER2)–positive locally recurrent or metastatic breast cancer.

That finding, which emerged from the AVEREL trial, adds another wrinkle in the ongoing controversy regarding use of bevacizumab in breast cancer treatment.


For the primary endpoint of investigator- assessed PFS, conducted at a median follow-up of 26 months, the addition of bevacizumab resulted in a hazard ratio (HR) of 0.82 (P = 0.0775), compared with treatment with trastuzumab (Herceptin) and docetaxel alone. This difference was not statistically significant. Median investigator-assessed PFS was 16.5 months with bevacizumab versus 13.7 months without it.

In an assessment by an independent review committee (IRC), however, a significant improvement in PFS was seen with the addition of bevacizumab (hazard ratio, 0.72; P = 0.0162). Median IRC-assessed PFS was 16.8 months with bevacizumab, compared with 13.9 months without the drug.

* For a PDF of the full article, click in the link to the left of this introduction.

Bevacizumab improves survival in HER2-positive metastatic disease

Bevacizumab (Avastin) improved progression-free survival (PFS) when added to standard treatment in a study of more than 400 women with human epidermal growth factor receptor 2 (HER2)–positive locally recurrent or metastatic breast cancer.

That finding, which emerged from the AVEREL trial, adds another wrinkle in the ongoing controversy regarding use of bevacizumab in breast cancer treatment.


For the primary endpoint of investigator- assessed PFS, conducted at a median follow-up of 26 months, the addition of bevacizumab resulted in a hazard ratio (HR) of 0.82 (P = 0.0775), compared with treatment with trastuzumab (Herceptin) and docetaxel alone. This difference was not statistically significant. Median investigator-assessed PFS was 16.5 months with bevacizumab versus 13.7 months without it.

In an assessment by an independent review committee (IRC), however, a significant improvement in PFS was seen with the addition of bevacizumab (hazard ratio, 0.72; P = 0.0162). Median IRC-assessed PFS was 16.8 months with bevacizumab, compared with 13.9 months without the drug.

* For a PDF of the full article, click in the link to the left of this introduction.

Publications
Publications
Topics
Article Type
Display Headline
2011 San Antonio Breast Cancer Symposium: New therapies, genetic assays translate into early detection of recurrence, encouraging outcomes
Display Headline
2011 San Antonio Breast Cancer Symposium: New therapies, genetic assays translate into early detection of recurrence, encouraging outcomes
Legacy Keywords
San Antonio Breast Cancer Symposium, bevacizumab, HER2-positive, brachtherapy, genetic test, zoledronic acid, DCIS,
Legacy Keywords
San Antonio Breast Cancer Symposium, bevacizumab, HER2-positive, brachtherapy, genetic test, zoledronic acid, DCIS,
Article Source

PURLs Copyright

Inside the Article

Article PDF Media